Abstract
Lipid nanoparticles (LNPs) have proven their value for delivery of RNA medicines in the clinic. We argue that some critical needs should be addressed to facilitate and accelerate the next generation of LNPs for nucleic acid delivery, for the benefit of patients. These needs include i) automated platforms for combinatorial synthesis linked to high-throughput in vitro and in vivo screening systems; ii) mRNA and/or LNP reference materials; and iii) robust test methods and protocols.
